Christelle Ratignier-Carbonneil

🌍Spotlight on Resah Meet our Technical Expert in Healthcare Public Procurement, in charge of leading the Observational Study on European Healthcare & Procurement Environment across 12 Member States! 🔎 Who is the Resah? Resah is a public Central Purchasing Body that leverages the purchasing power of hospitals and nursing homes in France. Resah is the only Central Purchasing Body specialized in both healthcare and medical-social sectors in France. It offers more than 4000 public contracts in all the procurement segments, covering all hospital needs: medical (pharmaceuticals, medical devices, biomedical equipment, PPE…) and non-medical (ICT solutions, catering, energy…), from more than 700 suppliers, including 45% of SMEs. Today the public organization has more than 2100 beneficiaries, including almost all French public and non-for-profit hospitals, nursing homes but also other public organizations like the public health national agency. The procurement volume through Resah’s public contracts was € 2.8 billion in 2023. Resah is one of the key procurement players in the healthcare sector in France and Europe. Resah is the founding member of the EHPPA Association. 🚀 Resah’s Role in PROCURE As the leader of Work Package 2 (WP2), Resah is responsible of the 1st phase of the project, the Observational Study on European Healthcare & Public Procurement Environment, with the collaboration of UPM and 12 Country Leaders from the Member States. ·        Main objective of this part is to get a deep knowledge of the European public procurement landscape ·        After the setting of the Country nodes and the definition of the common means and standardised methodology, guided by Resah, the 12 Country Leaders have collected the information from their respective nodes of healthcare organisations ·        Resah is currently consolidating the data to build the 12 ID Cards including key information from the National healthcare system; the public procurement environment and the Public Procurement practices and Covid impacts per Member States ·        Resah will soon delivery the final report to the European Commission, made of the Study methodology, the 12 ID Cards, the comparative analysis and the final conclusions ·        This Observational Study will constitute useful knowledge resources that organisations from other Regions or Countries can refer to in the future, to better understand the different National Healthcare system and Public Procurement processes and practices across Europe Stay tuned to learn more about the other partners in the consortium and their roles in PROCURE project making healthcare procurement more resilient and efficient across the European Union! #HealthcareInnovation #EU4Health #EUfunded, #HealthUnion, #procureproject #PublicProcurement #ActiveAgeing #EUProjects #PROCURE #Resah #EHPPA

26

#EUnetCCC | The French National Authority of Health (HAS), is proud to be one of the EUnetCCC leading partners, together with 31 countries, joining forces and connecting energies to develop the European Network of Comprehensive Cancer Centers. The HAS is committed to develop an innovative European certification scheme through intense cooperation with its partners: Unicancer, Fédération hospitalière de France (FHF), Institut national du cancer, Alleanza Contro il Cancro, Oslo universitetssykehus, Institut Català d'Oncologia (ICO), Deutsche Krebsgesellschaft e. V. (DKG), Technische Universität Dresden, NIZP PZH-PIB, Uniwersytet Ekonomiczny we Wrocławiu, VUL Santaros klinikos. 𝐖𝐡𝐚𝐭 𝐟𝐨𝐫? - Improving equal access to high-quality cancer care for all citizens in Europe. - Building a European Network of Comprehensive Cancer Centers will allow European citizens, whoever they are, wherever they live, to access the best cancer care Europeans all together can provide. If you want to know how the HAS will address the challenge 👇 | Lionel Collet Amelie Lansiaux Patrick Méchain Mona Krichen Sophie ALBERT Muriel Santoro European Health and Digital Executive Agency (HaDEA) Thomas Dubois Romain Mignerat Vincent Ollivier Xavier Troussard #EU4Health #CancerCare

44

2 commentaires

"Adherence 2:0, New Approches" 💡 As an EntrepreNurse, I'm constantly seeking fresh perspectives and innovative approaches. Recently, I had the opportunity to lead a workshop about adherence and compliance in healthcare for physicians and nurses. It sparked a question: How can we adapt our strategies to the unique needs of different patient generations and the changing world we live in? Traditional methods might not resonate with patients today anymore. We need to explore innovative ways to engage patients in their treatment plans and to empower clinicians with new tools to collaborate with patients on improving adherence. The discussion was inspiring, and I'm excited to explore these possibilities further in our next sessions. #innovation #adhearance #complaince #nurses #physicians

82

12 commentaires

Looking forward to sharing my perspectives and hearing how others are approaching the global VC landscape at this session at #GRIC2024!

19

Healthcare policy world is on fire 🔥! Another day, another big announcement- #CMMI is making changes to the #EnhancingOncologyModel and reopening for new participants. The current #EOM had a much smaller footprint than it’s predecessor #OCM, so methodology changes could entice broader participation and more meaningful impact on #oncology care.

23

1 commentaire

📢 New Resource Available! We’re excited to announce the release of our most comprehensive regulation mapping of the French health data warehouse framework (Entrepôt de Données de Santé - EDS), now live in the resource section of our website. This mapping provides a detailed overview of the regulatory landscape, offering clear steps for compliance with CNIL - Commission Nationale de l'Informatique et des Libertés requirements. 🔍 What’s Inside? Our regulation mapping breaks down the EDS framework, its purpose, and who it applies to, along with the necessary actions—whether you’re a public entity or a private company needing CNIL approval. 💡 What You'll Gain This resource will help users navigate EDS framework, ensure legal compliance, and securely manage health data for research in France. A must-have guide for anyone involved in health data projects! https://lnkd.in/d7X8eQUn

8

🚀 The highlight of the Première ligne en santé/First Line in Health was the insights from the panel discussion on modernizing healthcare systems through digital tools and data interoperability! We heard from the following thought leaders: 🙌 Gurpreet (G.P.) Singh, VP of Interoperability at ELLKAY 🙌 Emmanuelle Lamoureux, Director General, Health Care Strategies at Health Canada | Santé Canada 🙌 Abhinav Kalra, Executive Vice President at Canada Health Infoway 🙌 David O'Toole, President & CEO at Canadian Institute for Health Information (CIHI) ✨ ✨ ✨ ✨ ✨ ✨ ✨ 🤳 Check out the video ✨ ✨ ✨ ✨ ✨ ✨ ✨ ✨ Here's a summary of key points: 👏 Collaboration is Key: The panel emphasized the importance of collaboration among various stakeholders, including government bodies, healthcare providers, and private sector partners, to drive the adoption of common standards and interoperable systems. 🤩 Benefits of Data Sharing: Instead of focusing solely on the risks, there's a need to recognize the vast opportunities that come with sharing health data. By breaking down silos and sharing information, we can improve patient care, enhance efficiency, and drive innovation in healthcare delivery. 🎯 Standardization Challenges: While the need for standards like #SNOMEDCT and #HL7 #FHIR is evident, the implementation process poses challenges. These include variations in how standards are interpreted and implemented across different regions and healthcare organizations. 🚦 Role of Legislation: There's a growing consensus that legislation could play a crucial role in mandating the adoption of common standards and accelerating progress toward interoperability. This would require a coordinated effort from federal and provincial/territorial governments, as well as input from industry stakeholders. 👉 Empowering Clinicians with AI: With the influx of data, especially through AI tools, there's a need to empower clinicians to efficiently access and utilize patient information during consultations. AI-driven solutions like patient summaries can provide comprehensive overviews, helping clinicians make informed decisions in shorter time frames. 💫 Data Transformation and Mapping: While achieving consensus on standards is essential, there's also a need for data transformation and mapping mechanisms to ensure seamless interoperability across different systems and standards. ⭐ Health Data Infrastructure as Utility: Viewing health data infrastructure as a critical utility akin to transportation or power systems underscores its importance. This perspective can drive collective efforts toward building robust and interoperable healthcare systems for the benefit of all Canadians. Bobby Gheorghiu Mireille Luc, Ph.D. Justin Saindon HIMSS Eastern Canada Chapter (HIMSS Section de l’Est du Canada) Ana Maria Palusci RN, PMP, MBA- Business Analytics, Applied AI/ML #HealthTech #DigitalHealth #Interoperability #HealthcareInnovation https://lnkd.in/egcCVwD9

29

1 commentaire

Proud to have Julian Rozenberg from Agence de l'innovation en santé visit us ! Launched in June 2021 by the President of the Republic as part of the Health Innovation 2030 plan and led by Lise ALTER, the Health Innovation Agency (AIS) is tasked with piloting and coordinating measures to promote innovations with a positive impact on patient health in France. 🎯 12 priority tasks are structured around 5 levers: Anticipating innovations and medical needs to guide public policies. Facilitating, accelerating, and simplifying the journey of an innovation, from its conception to its availability to patients. Supporting innovative project leaders at each stage of their journey. Investing to make France the leading innovative and sovereign European nation in health. Integrating prevention as a pivot for scaling up positive health outcomes for the French population.

56

2 commentaires

With new EU HTA regulations coming online next year, the continent's leading national-level HTA bodies have a crucial role to play in ensuring a comprehensive and holistic approach to healthcare evaluation and regulation. This is just one of the topics discussed in a frank and wide-ranging interview with Lionel Collet, president of France's Haute Autorité de Santé who describes how HAS has evaluated 200 products during the past two years under its unique early access procedures and outlines why HAS is addressing the complexities of mental health in its 2030 strategic plan. Get the full picture at: https://lnkd.in/ehS-cs8Y

2

We are in the age of self-service so having French patients declare on their own the sick leaves of a maximum 7 days makes total sense. After all, the Brits did it and survived :) The cost-benefit if just 10% of the 68 mil. French take just one such leave per year, counting 5 minutes to operate this in a system: more than 1/2 mil. hours of low-value-added work of the medical professionals saved. At the minimum SMIC of 11.65 EUR/hr, we're talking almost 6 mil. EUR/yr. A drop in a a bucket or a smart move? #rh #hr #cristinamihai https://lnkd.in/ezxXBs25

4

Writing an RFP for an automated #compounding solution for your hospital? Did you put power consumption on your list as a selection criterium? We think you should! Come and visit us at The European Association of Hospital Pharmacists (EAHP) BOOST event to discover what The Compounder can do! #EAHPBOOST #Pharmacy #HospitalPharmacy #HealthcareInnovation #AutomationInHealthcare #Florence2024 #PharmacyInnovation #HospitalPharmacists

7

⚕️In France, there are more than 2,000 HealthTechs!   The HealthTech sector is currently the most dynamic one of the healthcare market.  However, this exceptional trend hides major challenges for companies and healthcare systems, such as:   🔹 Access to funding, as HealthTech players are players who offer services and products that usually require substantial investments. 🔹 Market access, as the regulations for introducing new drugs, devices or medical equipments to the market are very complex and rapidly changing. 🔹 The creation of partnerships, as most players are small players, who need several partners, upstream or downstream of the value chain to carry out their development.   In this context, carving out a place in the HealthTech market may seem complicated, but there are ways to stand out from the crowd!   To find out how our team can support you in your HealthTech projects, click here 👉 https://lnkd.in/eRwJk5Ys   #healthtech #innovation #development #healthindustry #healthcare

18

1 commentaire

Exciting news! 🎉 After rigorous negotiations, the European Health Data Space (EHDS) has been adopted in the European Parliament’s plenary session, just in time before the #Europeanelections and the new mandate. 🗳️ 🇪🇺 What can the EHDS bring to healthcare in Europe? 🏥 This proposal has three defining objectives ✅:  - Allowing data-sharing to enhance patient care.  - Setting the rules for health records systems and wellness applications offered on the market.  - Harnessing the potential of health data to drive research and innovation in healthcare.  🔍 Let’s take a closer look at some of the key provisions: - The final agreement includes the right for individuals to opt out from sharing their electronic health data for secondary purposes. However, Member States may override the opt-out decisions in specific situations of public health interest.  - Member States have the flexibility to implement additional safeguards for highly sensitive data, such as full genome sequences, biobanks, and wellness application data.   - In contrary to the original Commission proposal, the final text introduces a specific article dedicated to safeguarding intellectual property rights and trade secrets.  - Storage and processing of personal health data will be performed in the EU in principle, with exemptions for territories covered by an adequacy decision subject to Article 45 GDPR.  - A self-certification scheme for the electronic health records system is to be placed on the market, through a digital testing environment to be developed by the European Commission.  What’s next? 🤔 While this crucial milestone has been achieved, the agreement will need to go through legal-linguistic translation to refine the language and legal aspects of the text. This means the new Parliament and Council are expected to vote on the final version of the text after summer. The EU institutions are aiming for formal adoption of the file in Q4 2024. 🍂📅 The Regulation will apply two years after entering into force. It is expected that the EHDS infrastructure and governance framework will be fully operational within three to five years. 🕒    #EHDS #EuropeanHealthDataSpace #EU

21

📢 Navigating the French Assurance Maladie’s 30 priorities. But what matters most ? Assurance Maladie’s latest report for 2025 outlines several key initiatives aimed at improving the French healthcare system. However, a critical examination reveals a stark contrast between the proposed measures and the financial realities of the system. 📉 Proposals Overview: 💊 Reducing Medical Waste: The plan to cut down on unused medical supplies is significant. However, without clear strategies for implementation, this goal may fall short of addressing the root causes of medical waste. 🩺 Chronic Disease Management: Systematic screenings for cardiovascular and chronic conditions are proposed. Yet, the report does not fully consider the added burden on the already strained healthcare workforce or ensure equitable access across all regions. 🧪 Improving Cancer Screenings: Expanding access to cancer screenings is a step forward. However, the report does not adequately address the low participation rates driven by cultural and socioeconomic barriers. 🧠 Mental Health: Enhanced support for mental health is needed, especially given the rise in antidepressant use among youth. Yet, the lack of concrete action plans and resource allocation could undermine these efforts. 👩‍⚕️ Women’s Health: The proposed cardiovascular screenings for postmenopausal women and improved management of endometriosis are important. However, these measures need to be part of a broader strategy to address gender disparities in healthcare access and outcomes. ♻️ Environmental Impact: The ambition to decarbonize healthcare is notable. Still, the financial strain of implementing these practices in an already strained system raises questions about the relevance, feasibility and timing of such initiatives. Critical Perspective: Frederic Bizard highlights a concerning gap between Assurance Maladie’s proposals and the financial realities. The report aims for €1.6 billion in savings by 2025, but with 70% of these savings expected from price reductions, 25% from tackling fraud, and only 5% from managing chronic diseases despite these conditions driving 80% of expense growth there are serious concerns about the effectiveness of these measures. The real challenge lies in bridging the gap between the proposed initiatives and the systemic realities. While the report outlines various measures, it often lacks a cohesive strategy and actionable plans, reflecting broader governance and execution issues. As we approach 2025, it is crucial that these proposals are not just theoretical but translate into meaningful, real-world improvements for the healthcare system. 🌍💡 Antoine Bassel Amer https://lnkd.in/d5b55d28 

6

As you already know, Semetis has been nominated for the prestigious AMMA Award in the Best Use of Data category for our work with Korian! In this case, we tackled the challenge of managing the negative brand image associated with elderly care homes. 💡 Curious about the details? Dive into Diane's insightful article to learn more about how we achieved this and why we believe this strategy deserves an AMMA Award! 🏆 🔗 https://lnkd.in/eWV4ZhSs Great job, Diane Tremouroux! Let's keep pushing the boundaries of digital marketing. #AMMAAwards #DigitalMarketing #DataDriven #ElderlyCare #ReputationManagement #AI #Innovation #TeamSemetis

29

A shocking diagnosis has just been made in China: a 19-year-old young man is said to be suffering from Alzheimer's disease. This discovery calls into question our knowledge of this pathology. How can we explain the early onset of this neurodegenerative disease? What implications for medical research? -- > NOT A SURPRISE ?.. BECAUSE INFECTIONS (LYME & CO) MAY TRIGGER THESE KIND OF DISEASES (stated in studies since 2006.. and till 2024) https://lnkd.in/earXTbj3 --------------------------- Updates in Alzheimer's disease: from basic research to diagnosis and therapies Abstract Alzheimer’s disease (AD) is the most common neurodegenerative disorder, characterized pathologically by extracellular deposition of β-amyloid (Aβ) into senile plaques and intracellular accumulation of hyperphosphorylated tau (pTau) as neurofibrillary tangles. Clinically, AD patients show memory deterioration with varying cognitive dysfunctions. The exact molecular mechanisms underlying AD are still not fully understood, and there are no efficient drugs to stop or reverse the disease progression. In this review, we first provide an update on how the risk factors, including APOE variants, infections and inflammation, contribute to AD; how Aβ and tau become abnormally accumulated and how this accumulation plays a role in AD neurodegeneration. Then we summarize the commonly used experimental models, diagnostic and prediction strategies, and advances in periphery biomarkers from high-risk populations for AD. Finally, we introduce current status of development of disease-modifying drugs, including the newly officially approved Aβ vaccines, as well as novel and promising strategies to target the abnormal pTau. Together, this paper was aimed to update AD research progress from fundamental mechanisms to the clinical diagnosis and therapies. https://lnkd.in/etyf-ZmD ----------- Un diagnostic bouleversant vient d'être posé en Chine : un jeune homme de 19 ans serait atteint de la maladie d'Alzheimer. Cette découverte remet en question nos connaissances sur cette pathologie. Comment expliquer l'apparition si précoce de cette maladie neurodégénérative ? Quelles implications pour la recherche médicale ? https://lnkd.in/eWXaGhMX

1

💙🩵💙 ! 🔵I found some time in this very busy week (found it 'cus wanted to find it 😉) to express a deep #gratitude to the IIAR Journals who featured here at #LinkedIn our group latest paper (Alexia Giro Vocel et al, Anticancer Research, 44: 4983-4994, 2024). 🔵🔵 I am particularly happy to realize that the journal and our group lifted and highlighted each other, and wanted to say it here to Dr George Delinasios, the Managing Editor of Anticancer Research, and, very likely, one of The Brains and The Moving Forces of the IIAR Journals. #doyouknow that the IIAR is a relatively small institution (take a look at the Home Page of www.iiar-anticancer.org), located in #Kapandriti (the #Attica peninsula, near #Athens, in #Greece), but with a #BigVision, established already in 1995 : to become one of the leading #independent #scientific institutions and publishers? And it's very likely (at least it's my #perception 😉) that all this is a #dream of a small group of people (if not of Dr Delinasios at the 1st place), who live in a #LittlePlaceBetweenHills and are making one dream become true. If I am right, then we share a similar #dream, #vision and - #perception. 🔵🔵🔵 Our PERCEPTION study revealed some #intriguing #facts, which might seem "illogical", such as the positive correlation between the #NLR and the tumor tissue CD8-FoxP3 lymphocyte ratio, BUT : several recent papers have demonstrated a great #heterogeneity of #neutrophils, calling for deeper research on these colorful blood cells, which, actually, have attracted me to #hematology and #cellbiology, many years ago (I was a child and saw them in one of my grandfather's books!). 🟠🟠🟠 So, all you who might have found some "weird" things about #neutrophils in #cancer, check your data, validate them in other cohorts, and if you find again the same thing, BELIEVE IN YOURSELF (= publish your findings!) 'cus #NeutrophilsAreNotNeutral ! To confirm this, I am inviting you to read the papers with PMIDs 37001504 and 39515330, as well as one more #LittlePaperWithBigVision, the PMID 37046691 (Hanh To, ... , Yazid Belkacemi, Nina Radosevic, Cancers, March 30, 2023), you will understand what I mean 😉! 💜💜💜 And #thanks again to the #visionaries from a #LittlePlaceAtTheBalkans (the IIAR) for making the #independent #scientific #publishing reality. We need it so much, to make true our wildest dreams, and show it to the whole world! GO ON WITH THIS FANTASTIC WORK! #cancerresearch #oncology #radiotherapy #immunotherapy #biomarkers #blood #bloodcells #gotoyourpathologist #PerceptionInOurBlood

13

1 commentaire

An older but still very relevant publication by Alain Golay about the health-economic impact of non-adherence to treatment. The obvious benefit of good adherence to treatment is an improvement of the condition, but there is so much more to gain. Think about the reduced risk of psycho-social complications, the more cost-effective use of healthcare resources, and the improved health-related quality of life. At Link2Trials we believe that improving adherence to treatment can already start in clinical research. This is why we have developed our ARM services, and why we are involved in the BEAMER project. Keep following Link2Trials and BEAMER to stay up to date as we will post more details about the amazing adherence model the team is developing! https://lnkd.in/e8pryAc8 #beamerproject #patientadherence #patientengagement #clinicalresearch #clinicalcare #clinicaloperations #healthcareinnovations #patientoutcomes #healtheconomics #healthcareprofessionals #healthinsurancepolicy #regulators

9